- Home
- Articles
-
10.5606/tgkdc.dergisi.2023.23748
Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
Akif Kavgacı1, Serdar Kula1, Fatma İncedere1, Semiha Terlemez1, Fatma Sedef Tunaoğlu1
1Department of Pediatrics, Division of Pediatric Cardiology, Gazi University Faculty of Medicine, Ankara, Türkiye
DOI : 10.5606/tgkdc.dergisi.2023.23748
Treprostinil was approved by the United States Food and
Drug Administration for use in the treatment of pulmonary
arterial hypertension in 2002. Intravenous or subcutaneous
treprostinil is used in pulmonary arterial hypertension patients
in the functional classes of II-IV to alleviate exercise-related
symptoms, or in cases where epoprostenol treatment should be
reduced due to side effects. In this article, we describe three
pediatric cases of pulmonary arterial hypertension in whom
subcutaneous treprostinil was used.
Keywords : Pulmonary arterial hypertension, subcutaneous, treprostinil
Viewed : 1912
Downloaded : 451